A new approach with anticoagulant development: Tailoring anticoagulant therapy with dabigatran etexilate according to patient risk

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 2, 2012, Pages 217-226

  Rosencher, Nadia ^a   Albaladejo, Pierre ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Anticoagulant drugs; Bleeding risk; Dabigatran etexilate; Orthopedic surgery; Venous thromboembolism

Indexed keywords

CREATININE; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLEEDING; BLOOD TRANSFUSION; CLINICAL PRACTICE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; GROUPS BY AGE; HUMAN; KIDNEY DYSFUNCTION; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; HEMORRHAGE; HUMANS; ORTHOPEDIC PROCEDURES; PYRIDINES; RISK FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84855876269     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.648614     Document Type: Review

References (79)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133:381S-453S (Pubitemid 351894916)
2. Dahl OE, Caprini JA, Colwell CW Jr, et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost 2005;93:860-96
3. Friedman RJ, Dahl OE, Rosencher N, et al. for the RE-MOBILIZE, RE-MODEL, Re-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty. A pooled analysis of three trials. Thromb Res 2010;126:175-82
4. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133:257S-98S (Pubitemid 351892969)
5. Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004;2:1058-70 (Pubitemid 40186077)
6. Arixtra European Public Assessment Report. Scientific Discussion. European Medicines Agency, 2004. Available from: http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Scientific-Discussion/human/000403/WC500027737.pdf [Last accessed 24 August 2011]
7. Lotke PA, Lonner JH. Deep venous thrombosis prophylaxis: better living through chemistry-in opposition. J Arthroplasty 2005;20(Suppl 2):15-17 (Pubitemid 41327552)
8. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009;120:2006-11
9. Cohen AT, Tapson VF, Bergmann JF, et al. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;2:387-94 (Pubitemid 351173321)
10. Arcelus JI, Monreal M, Caprini JA, et al. RIETE investigators. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE registry. Thromb Haemost 2008;99:546-51 (Pubitemid 351549291)
11. Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 2010;29:233-40
12. Lacut K, Le Gal G, Mottier D. Primary prevention of venous thromboembolism in elderly medical patients. Clin Interv Aging 2008;3:399-411
13. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002;45:1757-66 (Pubitemid 34415371)
14. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98:155-62 (Pubitemid 47078782)
15. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85 (Pubitemid 47617868)
16. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56 (Pubitemid 47393577)
17. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
18. Eriksson BI, Dahl OE, Huo MH, et al. the RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721-9
19. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
20. Dahl OE. Dabigatran etexilate: an oral direct thrombin inhibitor. Therapy 2008;5:685-95
21. Pradaxa® Summary of Product Characteristics. Boehringer Ingelheim International GmbH, D-55216 Ingelheim am Rhein, Germany, 2011. Available from: http://www.emc. medicines.org.uk/medicine/20760/SPC/ Pradaxa+110+mg+hard+capsules/[Last accessed 24 August 2011]
22. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004;2:1573-80 (Pubitemid 40186173)
23. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-11 (Pubitemid 41647122)
24. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
25. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75 (Pubitemid 351930851)
26. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
27. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86 (Pubitemid 351930852)
28. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
29. Turpie AG. Rivaroxaban for the prevention and treatment of venous thromboembolism. Fundam Clin Pharmacol 2011; [Epub ahead of print]
30. Abdulsattar Y, Bhambri B, Nogid A. Rivaroxaban (Xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor Xa inhibitor. Pharm Ther 2009;34:238-44
31. Dahl OE, Kurth AA, Rosencher N, et al. No difference detected in efficacy of dabigatran etexilate when initial dosing was delayed: a post hoc analysis of pooled data from the European pivotal phase III trials. J Bone Joint Surg 2009;92-B(SUPPIV):494
32. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61
33. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban, an oral, direct factor Xa inhibitor. Annual Meeting of the American Society of Hematology (Abstracts). Blood 2006;108:905
34. Food and Drug Administration. Xarelto approval letter. November 2, 2011
35. Patel MR, Mhaqffey KW, Garg JMS, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, ROCKET-AF trial. N Engl J Med 2011;365:883-91
36. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15
37. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98
38. Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010;3:652-60
39. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation, ARISTOTLE trial. N Engl J Med 2011;365:981-92
40. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006;117:569-77 (Pubitemid 43326144)
41. Rosencher N, Vielpeau C, Emmerich J, et al. ESCORTE group. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost 2005;3:2006-14 (Pubitemid 43086058)
42. Lie SA, Engesaeter LB, Havelin LI, et al. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand 2002;73:392-9 (Pubitemid 35013402)
43. Thaler HW, Roller RE, Greiner N, et al. Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. J Trauma 2001;51:518-21 (Pubitemid 33009637)
44. Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304
45. Eriksson BI, Agnelli G, Cohen AT, et al. EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-6
46. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006;88:386-91
47. Foss NB, Kristensen MT, Jensen PS, et al. The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion 2009;49:227-34
48. Mantilla CB, Horlocker TT, Schroeder DR, et al. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology 2002;96:1140-6 (Pubitemid 34462575)
49. Devereaux PJ, Xavier D, Pogue J, et al. POISE (PeriOperative ISchemic Evaluation) Investigators. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011;154:523-8
50. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-5 (Pubitemid 30457356)
51. Pola E, Papaleo P, Santoliquido A, et al. Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing total hip arthroplasty. J Bone Joint Surg Am 2004;86-A:57-61 (Pubitemid 38057337)
52. Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009;20:114-21
53. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991;63:385-90
54. Goudable C, Saivin S, Houin G, et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991;59:543-5
55. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-31 (Pubitemid 34260945)
56. Stobe J, Siegemund A, Achenbach H, et al. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther 2006;44:455-65 (Pubitemid 44540938)
57. Mahe I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007;97:581-6 (Pubitemid 46592936)
58. Mahe I, Gouin-Thibault I, Drouet L, et al. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging 2007;24:63-71 (Pubitemid 46148082)
59. Delavenne X, Zufferey P, Baylot D, et al. GETHCAM Study Group; POP-A-RIX Investigators. Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Thromb Haemost 2010;104:252-60
60. Levin A, Ben-Artzi M, Beckerman P, et al. Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium: a prospective, open-label, observational study. Drugs Aging 2009;26:77-85
61. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
62. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly: a systematic review. Drugs Aging 1999;14:303-12 (Pubitemid 29195346)
63. Pengo V, Legnani C, Noventa F, Palareti G; ISCOAT Study Group. (Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and risk of bleeding. Thromb Haemost 2001;85:418
64. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745-52
65. Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc 2005;53:655-9 (Pubitemid 41623489)
66. Campbell NR, Hull R, Brant R, et al. Aging and heparin-related bleeding. Arch Intern Med 1996;156:857-60 (Pubitemid 26119813)
67. Barras MA, Duffull SB, Atherton JJ, et al. Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol 2009;68:700-11
68. Arixtra summary of product characteristics. 2007. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000403/WC500027746.pdf [Last accessed 24 August 2011]
69. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800 (Pubitemid 29420474)
70. Alikhan R, Cohen AT, Combe S, et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-8 (Pubitemid 38581515)
71. Dahl OE, Kurth AA, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery. Blood (ASH Annual Meeting Abstracts) 2008;112:981
72. Dahl OE, Clemens A, Eriksson BI, et al. 150 mg dabigatran etexilate once daily has a good safety profile and comparable efficacy to enoxaparin for primary prevention of venous thromboembolism after total knee or hip replacement surgery in patients over 75 years of age. Presented at the European Federation of National Associations of Orthopaedics and Traumatology 10th Congress; 3 - 6 June 2009; Vienna, Austria
73. Dahl OE. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement: rationale for dose regimen. Clin Appl Thromb Hemost 2009;15(Suppl 1):17S-24S
74. Dahl OE, Kurth AA, Rosencher N, et al. Dabigatran etexilate 150 mg once daily for the prevention of venous thromboembolism after total knee or hip replacement surgery in the elderly and those with moderate renal impairment. J Thromb Haemost 2009;7(Suppl 2):695-6
75. Eriksson I, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-11 (Pubitemid 41647122)
76. Fisher WD. Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Can J Surg 2011;54:344-51
77. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22
78. Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin 2008;26:169-87 (Pubitemid 351506494)
79. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:55-63